Novartis Head Of Pharma Development James Shannon: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Recent deals with Chiron, Human Genome Sciences and NeuTec Pharma highlight Novartis’ strategic priorities.
You may also be interested in...
Novartis Institutes For Biomedical Research President Mark Fishman: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Head of firm’s research arm discusses Novartis’ drug discovery model, a growing pipeline of biologics and the company’s partnering strategy.
Novartis Institutes For Biomedical Research President Mark Fishman: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Head of firm’s research arm discusses Novartis’ drug discovery model, a growing pipeline of biologics and the company’s partnering strategy.
Genentech VP-Business Development Joseph McCracken: An Interview With "The Pink Sheet" DAILY (Part 2 of 2)
Partnership with Roche has been the "ultimate win/win deal," McCracken says.